Released Nov 5, 2015, after the close
10-Q filed Nov 5, 2015, 36 days after period end · 0001171843-15-006060
Q3 2015 · 10-Q
Revenue$25.73M$25.73M +1.1% vs Q3 2014−10.7% vs Q2 2015
Net Income-$847.00K-$847.00K N/M vs Q3 2014N/M vs Q2 2015
EPS Diluted-$0.02-$0.02 N/M vs Q3 2014N/M vs Q2 2015
Gross Profit$11,726,000+2.5%
Operating Income-$775,000N/M
Operating Cash Flowderived-$78,000N/M
Margins · derived
Gross margin45.6%+0.6 pt vs Q3 2014
Operating margin-3.0%−8.6 pt vs Q3 2014
Net margin-3.3%−5.8 pt vs Q3 2014
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q3 2015 | Q3 2014 | Q3 2013 | Q3 2012 |
|---|---|---|---|---|
| Revenue | $25.73M | $25.45M | $25.14M | $26.10M |
| Net Income | -$847.00K | $633.00K | -$984.00K | -$133.00K |
| EPS Diluted | -$0.02 | $0.02 | -$0.03 | -$0.01 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Harvard Bioscience Inc · CIK 1123494 · Engraved from SEC EDGAR